Categories: COVID-19NewsVaccine

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.

A live webcast of the call will be available under “Events and Presentations” in the Investors section of the Moderna website.

The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

3 hours ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…

3 hours ago

Illumina completes acquisition of SomaLogic

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…

3 hours ago

RazorMetrics Drives More Than $11 Million in Prescription Drug Savings for Ohio Plans and Residents

AUSTIN, Texas, Jan. 30, 2026 /PRNewswire/ -- RazorMetrics, a leading innovator in pharmacy cost containment…

3 hours ago

NYSE Content Advisory: Pre-Market Update + Cast of HBO’s ‘Industry’ Rang Thursday’s Closing Bell

NEW YORK, Jan. 30, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…

3 hours ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national…

3 hours ago